- Home
- ENLT vs BLCO Comparison
ENLT vs BLCO Comparison
Compare ENLT & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENLT
- BLCO
- Stock Information
- Founded
- ENLT 2008
- BLCO 1853
- Country
- ENLT Israel
- BLCO Canada
- Employees
- ENLT N/A
- BLCO N/A
- Industry
- ENLT
- BLCO Ophthalmic Goods
- Sector
- ENLT
- BLCO Health Care
- Exchange
- ENLT Nasdaq
- BLCO Nasdaq
- Market Cap
- ENLT 5.2B
- BLCO 5.2B
- IPO Year
- ENLT 2023
- BLCO 2022
- Fundamental
- Price
- ENLT $37.23
- BLCO $15.55
- Analyst Decision
- ENLT Hold
- BLCO Hold
- Analyst Count
- ENLT 5
- BLCO 14
- Target Price
- ENLT $34.40
- BLCO $16.69
- AVG Volume (30 Days)
- ENLT 30.0K
- BLCO 580.9K
- Earning Date
- ENLT 11-12-2025
- BLCO 10-29-2025
- Dividend Yield
- ENLT N/A
- BLCO N/A
- EPS Growth
- ENLT 132.72
- BLCO N/A
- EPS
- ENLT 0.96
- BLCO N/A
- Revenue
- ENLT $457,756,000.00
- BLCO $4,976,000,000.00
- Revenue This Year
- ENLT $355.90
- BLCO $8.12
- Revenue Next Year
- ENLT $42.83
- BLCO $5.81
- P/E Ratio
- ENLT $39.02
- BLCO N/A
- Revenue Growth
- ENLT 27.72
- BLCO 6.23
- 52 Week Low
- ENLT $14.01
- BLCO $10.45
- 52 Week High
- ENLT $39.62
- BLCO $20.71
- Technical
- Relative Strength Index (RSI)
- ENLT 58.03
- BLCO 52.94
- Support Level
- ENLT $34.55
- BLCO $14.44
- Resistance Level
- ENLT $38.68
- BLCO $16.81
- Average True Range (ATR)
- ENLT 1.33
- BLCO 0.66
- MACD
- ENLT -0.20
- BLCO -0.08
- Stochastic Oscillator
- ENLT 67.11
- BLCO 46.84
About ENLT Enlight Renewable Energy Ltd.
Enlight Renewable Energy Ltd develops, finances, constructs, owns, and operates utility-scale renewable energy projects. The company's operating segments are the MENA segment, Europe segment, U.S.A segment, and Others. It generates the majority of its revenue from the Europe segment, which produces its revenue from the sale of the electricity that is produced through wind energy and solar energy in Europe.
About BLCO Bausch + Lomb Corporation
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.